Stock Price & Analysis

Based on the technical and fundamental analysis of INSP stock, here is a concise assessment:

Technical Analysis:

• Current price at $177.32, showing bearish momentum with RSI at 40.70 (oversold territory)
• Trading below both 5-day SMA ($180.02) and 20-day SMA ($186.39)
• MACD indicates negative momentum with -2.62 reading
• Price is near the lower Bollinger Band ($168.74), suggesting potential oversold conditions

Recent Insider Activity:

• Multiple insider sales in February 2025:
  • Randy Ban sold 3,341 shares (~$624K)
  • CTO John Rondoni sold 583 shares (~$99K)
• No insider purchases reported in the last 6 months

Institutional Sentiment: Mixed institutional sentiment with:

• 170 institutions increasing positions
• 210 institutions decreasing positions

Based on the analysis, SELL recommendation at current levels due to:

• Negative technical indicators
• Consistent insider selling pattern
• More institutions reducing positions than adding

Based on the provided data and market analysis, here is the price prediction for INSP stock in 2025:

The stock is expected to trade around $225-235 by end of 2025. This projection is based on several key factors:

1. Strong revenue growth trajectory with 2024 revenue reaching $802.8M and healthy gross margins of 84.68%

2. Technical analysis shows the stock is currently in a consolidation phase with strong support at $168 (Fibonacci S2) and resistance at $189 (Fibonacci R1)

3. Current valuation metrics indicate room for expansion:

• P/E ratio of 105.82x
• EV/EBITDA of 119.71x
• Strong balance sheet with zero debt and current ratio of 7.13x

The price target assumes continued execution on growth strategy and maintenance of profitability metrics. Key risks include competitive pressures and potential market volatility impacting high-growth medical device stocks.

The S1 support level for INSP Stock is $173.04 ,The R1 resistant level for INSP Stock is $189.07.

As of the end of day on 2025-02-21, the price of INSP Stock was $177.32.

The target price for INSP Stock according to analyst rating is 232.92, with the highest price target at 270.00 and the lowest at 190.00. Analysts have a Moderate Buy rating on INSP Stock overall.

The market cap of INSP is $5.3B.

Based on the technical and fundamental data analysis, INSP appears to be overvalued at current levels. The stock's RSI-14 reading of 40.70 indicates neutral momentum but trending towards oversold territory, while the negative MACD (-2.62) suggests bearish momentum. The company's financial metrics show concerning trends with negative net income (-$21.15M in FY2023) despite revenue growth to $624.8M. Recent insider selling activity, with multiple executives disposing shares and no purchases in the past 6 months, raises additional red flags. The current price of $177.32 is trading below multiple key moving averages (SMA-20: $186.39, SMA-60: $188.73), suggesting technical weakness.

Inspire Medical Systems, Inc. is a medical technology company. The Company is focused on the development and commercialization of advanced, minimally invasive solutions for patients with obstructive sleep apnea (OSA). Its proprietary Inspire system is the FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. The Company has developed a novel, closed-loop solution that continuously monitors a patient’s breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The Company sell its Inspire system to hospitals and ambulatory surgery centers (ASCs) in the United States (U.S.) and in select countries in Europe and Japan through a direct sales organization and sells its Inspire system in Singapore and Hong Kong through distributors. Its direct sales force engages in sales efforts and promotional activities focused on ENT physicians and sleep centers.

Based on the available data and market analysis, here is the price prediction for INSP stock by 2030:

INSP stock is projected to reach $350-375 by 2030, representing a ~100% upside from current levels around $177. The growth will likely be driven by continued market expansion in sleep apnea treatment devices and strong execution of the company's commercialization strategy. Recent insider selling activity suggests some near-term caution, but the long-term growth trajectory remains intact based on the expanding addressable market.

The prediction factors in:

• Historical growth trajectory showing resilience despite market volatility
• Strong competitive position in sleep apnea treatment market
• Current technical indicators suggesting consolidation phase before next leg up

INSP has a total of 1011 employees.